Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know

In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates

BenzingaMay 15 23:01

HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.

HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.

Zhitong FinanceMay 15 22:40

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $5 price target.

BenzingaMay 15 22:34

Sangamo Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 776.73% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/19/2024 776.73% HC Wainwright & Co. $3

BenzingaMay 15 22:33

US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results

Yahoo FinanceMay 12 21:17

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 12 20:28